Objectives: We previously constructed a trimeric coiled coil, N28Fd, based on the N-heptad repeat (NHR) sequence of HIV-1 gp41, as a promising HIV-1 entry inhibitor. Here, we attempted to engineer a stabilized trimeric coiled coil, ccN28Fd, by adding interchain disulphide bonds at the N terminus of N28Fd to improve its biophysical properties and anti-HIV-1 efficacy.
Introduction
Unprotected heterosexual contact is the primary mode of HIV transmission in developing countries, and it is becoming an increasing risk factor in developed countries. 1 Most new infections among women in Asia are contracted from their husbands. 2 Hence, it is of great importance to develop microbicides to prevent sexual transmission of HIV.
Previous studies focused on the development of the nonspecific anionic polymer-based microbicides, such as naphthalene sulfonate (PRO2000), 3, 4 carrageenan (Carraguard) 5, 6 and cellulose sulphate (Ushercell). 7 -9 These microbicides inhibit HIV entry into host cells by interacting with the HIV envelope proteins (Env), mainly through anionic interaction and the disruption of HIV attachment to CD4 + cells. Unfortunately, results from clinical trials showed that they failed to demonstrate efficacy in preventing HIV-1 acquisition, partially because of their limited efficacy against CCR5-tropic HIV-1 strains, which constitute the most common phenotype transmitted by the sexual route. 10, 11 Recent studies have shifted towards developing microbicides based on the small-molecule HIV reverse transcriptase inhibitors (RTIs), including nucleoside reverse transcriptase inhibitors (NRTIs), such as tenofovir, 12, 13 and non-nucleoside reverse transcriptase inhibitors (NNRTIs), e.g. TMC-120. 14, 15 A Phase IIb clinical trial (CAPRISA 004 trial) of 1% tenofovir clinical trial gel as a microbicide in South Africa showed that participants who used tenofovir gel before and after sex exhibited lower HIV acquisition with, an estimated reduction of 39% overall and 54% with high gel adherence. 16 However, RTI-based microbicides may not be effective against RTI-resistant HIV-1 strains. RTIs, as the major components in antiretroviral therapy (ART), have been widely used in clinics. Therefore, many HIV-1 isolates are already resistant to RTIs when they are transmitted from ART-treated HIV-1-infected patients to uninfected persons. Therefore, development of microbicide combinations consisting of RTIs and HIV-1 entry inhibitors is urgently needed for preventing HIV sexual transmission. 17 The first HIV-1 entry inhibitor approved by the US FDA for treating HIV-1-infected patients who failed to respond to the current ART was enfuvirtide (brand name Fuzeon, generic name enfuvirtide), which is a synthetic peptide derived from the C-terminal heptad repeat (CHR) region of HIV-1 gp41. 18 -20 Enfuvirtide and other CHR peptides, such as C52-L, 21 sifuvirtide 22 and L644, 23 have been used for developing anti-HIV microbicides. However, CHR peptides are unstructured in solution according to biophysical and structure analysis, and they are unstable in the vaginal environment, which has a low pH (3.8 -4.4) and abundant proteolytic enzymes. 24 -27 Therefore, it is preferable to develop microbicides based on a trimeric coiled coil formed by the peptides derived from the N-terminal heptad repeat (NHR) region. The NHR trimers inhibit HIV fusion by binding to the viral gp41 CHRs 28 -30 or by disrupting the formation of inner NHR trimers. 31 We previously designed an NHR trimer, designated N28Fd, consisting of a 28-mer NHR peptide fused with a T4 fibritin trimerization motif, foldon (Fd), as an anti-HIV-1 microbicide. Compared with the original N28 peptide, N28Fd showed much improved anti-HIV-1 potency. 25 However, we found N28Fd to be sensitive to proteolytic enzymes and low pH and that it had lower anti-HIV-1 activity than enfuvirtide. Therefore, in this study, we introduced intermolecular disulphide bonds by adding two cysteines at the N terminus of N28Fd in order to stabilize the trimeric coiled coil ( Figure 1 ). As expected, this newly engineered recombinant protein, designated ccN28Fd, exhibited much improved thermostability and resistance to proteolytic enzymes and low pH. Its anti-HIV-1 activity was significantly improved 10-fold over that of N28Fd. Seminal fluid (SF) and vaginal fluid simulant (VFS) had no effect on its antiviral potency. Combining ccN28Fd with tenofovir resulted in strong synergism. These results suggest that ccN28Fd can be further developed as an effective and stable component in a novel microbicide combination.
Materials and methods

Reagents
Peptides C34 (amino acids 628-661) and enfuvirtide (amino acids 638-673) were synthesized by a standard solid-phase FMOC [N- (9- methoxycarbonyl method as described previously. 32 Both peptides bear an acetyl group at the N terminus and an amide group at the C terminus. The peptides were purified to homogeneity (.95% purity) by HPLC and verified by mass spectrometry. Proteinase K-agarose, pepsin, phytohaemagglutinin (PHA), interleukin-2 (IL-2) and XTT were purchased from Sigma (St Louis, MO, USA). SF was purchased from Lee Biosolutions, Inc. (St Louis, MO, USA). VFSwas prepared as described by Owen and Katz. 33 GFP (green fluorescent protein)-transduced human osteosarcoma (Ghost) cells, which express CD4 and coreceptors CCR5 and CXCR4, were kindly provided by Dr Linqi Zhang at Tsinghua University. The cells (HEK 293T, MT-2 and TZM-bl), the anti-HIV drug tenofovir, the laboratory-adapted HIV-1 strains IIIB and Bal, and the primary HIV-1 isolates, as well as the HIV-1 enfuvirtide-resistant strains, including NL4-3(36G)V38A, NL4-3(36G)V38A/N42D, NL4-3(36G)N42T/N43K, NL4-3(36G)V38A/N42T and NL4-3(36G)V38E/N42S, and the plasmids (pNL4-3.Luc.R -E -and pHXB2-Env) were obtained from the NIH AIDS Research and Reference Reagent Program. VK2/E6E7 cells were purchased from ATCC (Manassas, VA, USA).
Plasmid construction
The plasmid encoding N28Fd was constructed as described previously 25 and used to create the vectors encoding ccN28Fd and N28FdE5R, respectively, using a standard point mutation method by PCR. The resultant ccN28Fd should contain four residues (CCGG) at the N terminus of N28Fd, while N28FdE5R should bear a Glu (E) Arg (R) mutation at the fifth residue of Fd. The DNA fragments were cloned into the BamHI and XhoI sites of pGEX-6p-1 vector (GE Healthcare, Sweden).
Expression and purification of the recombinant proteins
Each of the recombinant plasmids was transformed into Escherichia coli strain Rosetta. The recombinant protein N28Fd was induced at 308C with 0.4 mM IPTG for 5 h, while ccN28Fd and N28FdE5R were induced at 168C for 12 h. The recombinant proteins with glutathione S-transferase (GST) tags were first purified with a standard procedure using glutathione Sepharose 4B Fast flow beads (GE Healthcare, Sweden), followed by further purification on a Superdex-200 column (GE Healthcare, Sweden) with elution buffer of acetic acid-sodium acetate solution (100 mM, pH 5.0). For ccN28Fd, oxidization was performed by adding oxidized and reduced glutathione to final concentration of 9 mM and 0.9 mM, respectively. After 5 days, the protein was dialysed against appropriate buffer. The purified proteins were analysed with SDS-PAGE, and their concentrations were determined with absorbance at UV280.
Sedimentation velocity analysis (SVA)
All measurements were performed on the Proteomelab TM XL-A/XL-I analytical ultracentrifuge (Beckman Coulter, Fullerton, CA, USA) at 208C as previously described. 25 In brief, three-channel cells were used with an An-60 Ti rotor. The recombinant proteins were dialysed against acetic acid/sodium acetate solution (100 mM, pH 6.0). Each of the proteins was mixed with equimolar C34 in PBS (150 mM Na 2 HPO 4 , 2.5 mM NaH 2 PO 4 and 150 mM NaCl, pH 7.2) and incubated at 378C for 30 min. All samples were prepared at final concentration of 50 mM and were initially scanned at 3000 rpm for 10 min to identify the appropriate wavelength for data collection. Data were collected at 60 000 rpm at wavelengths of 280 nm. Sedimentation coefficient distribution, c (s), and molecular mass distribution, c (M), were calculated using the SEDFIT program.
Circular dichroism (CD) analysis
The secondary structure and a melting temperature (T m ) of the recombinant proteins were analysed by CD spectroscopy as previously described. 34 Briefly, the individual proteins and their mixtures with C34 peptide (at equimolar concentration) were prepared in PBS at final concentration of 10 mM and incubated at 378C for 30 min. Data were acquired on an Applied Photophysics Pi-Star 180 spectropolarimeter (Applied Photophysics, UK) at a 3 nm bandwidth, 0.1 nm resolution, 0.1 cm path length, 1 nm wavelength interval from 200 to 260 nm and corrected by subtraction of a blank corresponding to the solvent. The content of a-helix was determined from the CD signal by dividing the mean residue ellipticity at 222 nm by the value expected for 100% helix formation (33000 degrees cm 2 dmol
21
). 35 Thermal denaturation of the recombinant proteins and their complexes with C34 peptide was assessed at 208 nm by monitoring a temperature gradient from 158C to 908C with a 18C interval.
Analysis of single-cycle pseudovirus infection
Single-cycle pseudovirus infection assay was performed as previously described. 36, 37 In brief, pseudoviruses were packaged by transient transfection of HEK 293T cells with pNL4-3.LucR -E -and pHXB2. The titre of pseudovirus was determined by 2-fold dilution in 1×10 5 Ghost cells to final volume of 200 mL. The sample containing the residual inhibitor (50 mL) and pseudovirus (50 mL) was incubated at 378C for 1 h and then added to Ghost cells (100 mL). The cells were then cultured at 378C in 5% CO 2 for 48 h, and the relative luminescence units (RLU) were detected with a luciferase kit (Promega, Madison, WI, USA) and luminometer (Ultra 386, Tecan, Durham, NC, USA).
Assay for sensitivity to proteolytic degradation by proteinase K and pepsin
Assay for neutral proteolytic degradation of N28Fd and ccN28Fd by proteinase K was performed as previously described. 25 Briefly, the proteins (50 mg/ mL) were prepared in PBS (pH 7.2) containing 38 microunits/mL proteinase K-agarose. Samples were harvested at different time intervals and centrifuged immediately. The supernatants were stored at 2208C. Assay for acid proteolytic degradation by pepsin (1: 10000) was conducted as described before. 24 The proteins (100 mg/mL) were prepared in water adjusted with HCl to pH 1.5. Samples were harvested at different time intervals, neutralized with equal volume of NaOH immediately and incubated at 608C for 10 min. Samples were kept at 2208C before use. The residual protein concentration and the residual antiviral activity in each sample were detected by ELISA 25 and single-cycle infection as described above.
Measurement of anti-HIV-1 activity of ccN28Fd
The antiviral activity of the peptides/proteins against infection by HIV-1 IIIB (X4) and enfuvirtide-resistant strains was determined as previously described. 38 Briefly, 1×10 4 MT-2 cells were infected with an HIV-1 strain at 100 TCID 50 (50% tissue culture infected dose) in 200 mL culture medium in the absence or presence of an inhibitor at graded concentration overnight. The culture supernatants were then changed with fresh medium. On the fourth day post-infection, 100 mL of culture supernatants was collected from each well, mixed with equal volumes of 5% Triton X-100, and assayed for p24 antigen by ELISA.
The inhibitory activity of the proteins/peptides on infection by HIV-1 Bal strain and HIV-1 HXB2 pseudovirus was determined as described before. 39 Briefly, 1×10
4 TZM-bl cells were infected with 100 TCID 50 of viruses with or without the serially diluted inhibitors. On the fourth day post-infection, the culture supernatants were discarded, and the cells were lysed with 50 mL of lysing buffer. Relative luminescence units (RLU) were detected with a luciferase kit (Promega) and luminometer (Ultra 386, Tecan).
The inhibitory activity of the proteins/peptides on infection by primary HIV-1 isolates was determined as previously described. 38 Briefly, the peripheral blood mononuclear cells (PBMC) were isolated from the blood of healthy donors using a standard density gradient (Histopaque-1077, Sigma) centrifugation. After incubation at 378C for 2 h in 75 cm 2 flasks, Engineered gp41 trimer-based anti-HIV-1 microbicide the non-adherent cells were collected and resuspended at 5×10 5 /mL in RPMI 1640 medium with 10% fetal bovine serum (FBS), 5 mg/mL of PHA and 100 units of interleukin-2/mL, followed by incubation at 378C for 3 days. The PHA/IL-2-stimulated cells were infected with the primary HIV-1 isolates at a multiplicity of infection (moi) of 0.01 without or with the test inhibitors at graded concentrations. The culture supernatants were harvested 7 days post-infection and assayed for p24 antigen by ELISA.
The half maximal inhibitory concentration (IC 50 ) of an inhibitor was calculated using the Calcusyn software, 40 kindly provided by Dr T. C. Chou at Sloan-Kettering Cancer Center, New York, NY, USA.
Detection of inhibitory activity on HIV-1 transmission from PBMCs to CEMx174 5.25M7 cells
The inhibitory activity of ccN28Fd on cell-to-cell HIV-1 transmission was determined as previously described. 41 PHA/IL-2-stimulated PBMCs were infected with HIV-1 Bal at moi of 0.01 for 7 days as described above. The infected cells were washed with PBS three times to remove free viral particles and resuspended in culture medium to 1×10 5 /mL. Then, 50 mL of the cell suspension was incubated with 50 mL of ccN28Fd at graded concentration at 378C for 30 min, followed by adding 100 mL of CEMx174 5.25M7 cells (2×10 5 /mL) and co-culturing at 378C for 3 days. The cells were harvested and lysed for analysis of luciferase activity as described above.
Combination study
The assays for evaluating HIV-1 IIIB and Bal infection were used to test the synergistic antiviral effect of the ccN28Fd/tenofovir combination as previously described. 42 The anti-HIV-1 activity of ccN28Fd and tenofovir was assessed individually, or in combination, at a fixed molar ratio for the greatest synergism over a range of serial dilutions. The analysis was executed progressively by calculating IC 50 43 Dose reduction was obtained by dividing the IC 50 value of a peptide tested alone by that of the same agent tested in combination with the other agent.
Assay for cytotoxicity
The cytotoxicity of ccN28Fd to the target cells (MT-2 cells and TZM-bl cells) used for testing HIV-1 infectivity and human vaginal epithelial cell line (VK2/ E6E7) was detected by XTT colorimetric assay as previously described. 44 Briefly, 100 mL of ccN28Fd at graded concentrations was added to 100 mL cells (1×10 5 /mL) each well. After incubation at 378C for 4 days, 50 mL of XTT solution (1 mg/mL) with 0.02 mM phenazine methosulfate (PMS) were added. After 4 h, the absorbance was measured at 450 nm.
Detection of the effects of hydroxyethylcellulose (HEC) gel, SF and VFS on anti-HIV-1 activities of ccN28Fd
The ccN28Fd gel formulation was prepared by mixing 100 mg of ccN28Fd with 0.1 g of the HEC gel (0.1%, w/w). After shaking or stirring at room temperature for 60 min, ccN28Fd was completely dissolved in the 0.1% w/w HEC gel, which was then tested for anti-HIV-1 activity against HIV-1 Bal. The effects of human SF and VFS on anti-HIV-1 activity were detected as previously described. 45, 46 SF was obtained by centrifugation of semen at 500 g for 30 min to remove spermatozoa. To avoid the toxic effect of SF and VFS on target cells and viruses, ccN28Fd was first diluted in SF, VFS or PBS at a concentration of 12.5 mM. After incubation at 378C for 60 min, the mixtures were diluted with culture medium 100-fold for testing antiviral activity against HIV-1 Bal and HIV-1 IIIB infection.
Results
Design, expression and characterization of ccN28Fd and N28FdE5R
To engineer a recombinant protein with increased stability and anti-HIV-1 activity, we introduced two cysteines into the N terminus of N28Fd (at positions d and e of the helical wheel of N28, respectively) to form three intermolecular disulphide bonds between the three subunits of a trimer. 47 By so doing, both the N and C termini of the N28-based helical trimer are expected be stabilized by the intermolecular disulphide bonds and Fd, respectively ( Figure 1 ). For the control protein N28FdE5R, we introduced a mutation, Glu
Arg at position 5 of the Fd fragment in N28Fd, to destabilize the helical trimer by removing an intermolecular salt bridge in Fd. 48 The full sequences and positions of ccN28Fd and N28FdE5R are shown in Figure 1(b) .
The plasmids encoding ccN28Fd, N28FdE5R and N28Fd were transformed into E. coli strain Rosetta. These proteins were then expressed and purified as described in the Materials and methods section. The newly engineered ccN28Fd was analysed by SDS-PAGE, with N28Fd as a control. The protein samples were treated with 2% SDS at room temperature without boiling. At pH 7.2, both ccN28Fd and N28Fd were trimers; however, at pH 3.0, only ccN28Fd retained trimeric conformation, whereas N28Fd became monomeric. N28FdE5R, as a control, was in monomeric form at pH 7.2 and pH 3.0 (Figure 2 ). This result suggests that similar to N28Fd, ccN28Fd maintains its trimeric conformation under both neutral and acidic pH, while N28Fd loses its trimeric conformation in an acidic environment.
The recombinant proteins ccN28Fd and N28Fd were further analysed by SVA. The sedimentation coefficient of ccN28Fd and N28Fd was 1.34s and 1.43s, corresponding to 22.6 and 18.3 kDa, Tong et al.
in agreement with the theoretical molecular mass for a ccN28Fd trimer (20.1 kDa) and N28Fd trimer (19.1 kDa), respectively ( Figure 3 ). The frictional coefficient (f/f 0 ) in SVA reflects shapedistribution of the protein tested. The f/f 0 value, which is calculated from experimental data using the SEDFIT program, allows for estimation of the extent to which the protein shape differs from a compact, unhydrated globular protein of the same mass and density. 49 The f/f 0 value of a globular, hydrated protein is 1.2-1.4, while a moderately elongated protein is 1.6 -1.9. The f/f 0 values of ccN28Fd and N28Fd were 1.93 and 1.66, respectively, indicating that the shape of ccN28Fd and N28Fd are moderately elongated.
The CD spectra and thermodynamic stability of these proteins were subsequently analysed. As shown in Figure 4 , ccN28Fd and N28Fd exhibited similar secondary structure, i.e. an atypical a-helix, presumably because of the presence of a b-sheet domain in Fd. 50 However, ccN28Fd had much higher melting temperature (T m ¼ 798C) than N28Fd (T m ¼ 648C), suggesting that ccN28Fd trimer with intermolecular disulphide bonds at its N terminus has much more thermostability than N28Fd.
Binding of ccN28Fd to the CHR domain of gp41
The ccN28Fd trimer is expected to mimic the pre-hairpin intermediate of HIV-1 gp41 for inhibiting HIV-1 entry into the target cell by binding with the viral gp41 CHR to block the fusogenic six-helix bundle core formation. We thus examined whether ccN28Fd (N28Fd as a control) could interact with C34 by SVA and CD. As analysed by SVA, the sedimentation coefficient of ccN28Fd/C34 complex and N28Fd/C34 complex was 2.49s and 2.11s, corresponding to 31.1 and 28.1 kDa, in agreement with the theoretical molecular mass for a ccN28Fd/C34 six-helix bundle (32.9 kDa) and N28Fd/C34 six-helix bundle (31.9 kDa), respectively ( Figure 3) . Data from CD analysis indicated that ccN28Fd/C34 complex was more stable (T m ¼ 778C) than N28Fd/C34 complex (T m ¼ 648C) (Figure 4 ). These results suggest that ccN28Fd is able to bind with the gp41 CHR peptide, C34, to form a six-helix bundle core with higher thermostability than that formed by N28Fd and C34.
Potent antiviral activity of ccN28Fd against a broad spectrum of HIV-1 strains and cell-to-cell transmission of HIV-1
We next tested the anti-HIV-1 activity of ccN28Fd, in comparison with N28Fd and enfuvirtide. As shown in Figure 5 (a), ccN28Fd effectively inhibited HIV-1 IIIB (subtype B, X4) infection in MT-2 cells with an IC 50 of 5.1 nM, which is 18.3-fold and 6.4-fold more potent than N28Fd (IC 50 ¼93.5 nM) and enfuvirtide (IC 50 ¼ 32.6 nM), respectively. The IC 50 value of ccN28Fd for inhibiting infection by HIV-1 Bal (subtype B, R5) infection was 3.7 nM, which is 23-fold and 10.2-fold more potent than N28Fd (IC 50 ¼ 85.1 nM) and enfuvirtide (IC 50 ¼ 37.6 nM) (Figure 5b ). We further evaluated the antiviral activity of ccN28Fd against a panel of primary HIV-1 isolates of group M, including subtypes A, B, C, D, F, A/E and group O (BCF02). As shown in Table 1 , ccN28Fd effectively inhibited these primary isolates with low nanomolar IC 50 , ranging from 3 to 75 nM. We also tested whether ccN28Fd was effective against HIV-1 variants resistant to enfuvirtide, the only FDA-approved HIV-1 entry inhibitor targeting gp41. Five enfuvirtide-resistant strains 51 with mutations in the gp41 NHR region were used in this experiment. HIV-1 NL4-3(36G)V38A strain with a single mutation was moderately resistant to enfuvirtide (IC 50 ¼943 nM), while those with double mutations, including HIV-1 NL4-3(36G)V38A/N42D , HIV-1 NL4-3(36G)N42T/N43K and HIV-1 NL4-3(36G)V38A/N42T strains, were highly resistant to enfuvirtide (IC 50 .2000 nM). Strikingly, ccN28Fd showed high potency against enfuvirtide-resistant strains with IC 50 values in a range of 2 -13 nM (Table 2) . We then tested whether ccN28Fd inhibited cell-to-cell spread of HIV-1, which permits ongoing replication of drug-resistant HIV-1 strains. 52 As shown in Figure 6 Figure 3 . Sedimentation velocity analysis of ccN28Fd and the ccN28Fd/C34 mixture (a) and N28Fd and the N28Fd/C34 mixture (b). The recombinant proteins ccN28Fd and N28Fd in 100 mM CH 3 COONa/CH 3 COOH buffer and their complexes with C34 in PBS (pH 7.2) were monitored. The sedimentation coefficient (s) and molecular mass (kDa) of each peak are indicated. The experiment was repeated once, and a similar result was obtained.
and phenotypes (X4, X4/R5 and R5) and is also effective in blocking cell-to-cell transmission of HIV-1.
Combining ccN28Fd with tenofovir resulted in highly potent synergistic anti-HIV-1 activity High resistance of ccN28Fd to proteolytic degradation by proteinase K and pepsin
Numerous antiviral proteins and peptides have potent anti-HIV-1 activity; however, they rapidly degrade in the vaginal environment with abundant proteolytic enzymes under low pH (3.8 -4.4). 27 The engineered protein ccN28Fd, a compact trimeric coiled coil structure stabilized by intermolecular disulphide bonds and Fd, is . CD spectra and thermal denaturation curves of separated NHR proteins, or mixture of NHR proteins and C34, as determined by CD spectroscopy. CD spectroscopy was used to determine the secondary structure of ccN28Fd and N28Fd (a) and the mixture of ccN28Fd and N28Fd with C34, respectively (b). CD spectra of each protein and their complexes with C34 were monitored in PBS, pH 7.2, at ambient temperature. The final concentration of the peptide or protein was 10 mM. The melting temperature (T m ) for ccN28Fd or N28Fd (c) and their complexes with C34 (d) are shown in the figure. The experiment was repeated once, and a similar result was obtained.
expected to be more resistant to the proteolytic enzymes than N28Fd. We thus compared their sensitivity to proteinase K, a broadspectrum serine protease, in neutral solution and pepsin in acid solution. As shown in Figure 7 , after treatment with 38 microunits/mL proteinase K in PBS (pH 7.2) for 4 h, ccN28Fd retained more than 99% of the original amount and 90% of its anti-HIV-1 activity, while N28Fd was completely degraded and lost its anti-HIV-1 activity. After treatment with 10 nM of pepsin in HCl (pH 1.5) The assay was performed in triplicate and repeated at least once. The data are presented as means+SD from one representative experiment. Enfuvirtide was included as a control. The experiment was performed in triplicate and repeated at least once. The data are presented as means+SD from one representative experiment.
Enfuvirtide was included as a control. Engineered gp41 trimer-based anti-HIV-1 microbicide for 4 h, ccN28Fd retained 89% of the original amount and 100% of its anti-HIV-1 activity, while N28Fd retained only 30% of the original amount and completely lost its anti-HIV-1 activity. These results indicate that the newly engineered ccN28Fd is much more resistant to proteolytic degradation by proteinase K and pepsin than the unmodified N28Fd.
No significant effect of SF, VFS and HEC gel on ccN28Fd-mediated anti-HIV-1 activity
The efficacy of topical microbicides can be affected by human body fluids, such as seminal plasma and vaginal secretions. 53 Therefore, we tested the effect of SF and VFS on the anti-HIV-1 activity of ccN28Fd. As shown in Figure 8 , the inhibition activity of ccN28Fd against HIV-1 IIIB and Bal strains was not significantly affected by SF or VFS. The IC 50 values of ccN28Fd for inhibiting HIV-1 IIIB infection in the presence of SF and VFS were 10.33 and 9.51 nM, respectively, while that in PBS control was 11.23 nM. The IC 50 values of ccN28Fd for inhibition of HIV-1 Bal infection in the presence of SF and VFS were 5.39 and 4.79 nM, respectively, while that in PBS control was 4.13 nM. Furthermore, ccN28Fd released from the HEC gel formulation exhibited antiviral potency similar to that in PBS control ( Figure S1 , available as Supplementary data at JAC Online). These results suggest that ccN28Fd can be formulated in HEC gel as a topical microbicide with potent antiviral activity that is not affected by human seminal and vaginal fluids.
No significant cytotoxicity of ccN28Fd
An ideal microbicide should have no toxic effect on human cells and tissues, particularly the mucosal tissues in the genital tracts. Using an XTT assay, we tested whether ccN28F had any in vitro cytotoxicity to the target cells (MT-2 and TZM-bl) used for evaluating anti-HIV-1 activity and the human vaginal epithelial cell lines (VK2/E6E7). As shown in Figure S2 (available as Supplementary data at JAC Online), ccN28Fd did not show significant cytotoxicity to these cells at the concentration as high as 10 mM. This result suggests that ccN28Fd may not have toxic effect on human immune cells or vaginal/cervical tissues, if it is applied as a topical microbicide.
Discussion
For developing an HIV-1 fusion/entry inhibitor-based microbicide, we previously designed an NHR-trimer, N28Fd, 25 by fusing the trimerization motif Fd to the C terminus of N28 peptide ( Figure 1 ). As expected, N28Fd exhibits a trimeric conformation and has better anti-HIV-1 activity than N28. However, it is not an ideal anti-HIV microbicide candidate since it is sensitive to low pH and protease treatments, possibly because the N termini of the three N28 peptides in the N28Fd trimer may not be tightly associated. To solve this problem, we engineered a new protein, ccN28Fd, by adding four amino acids, CCGG, to the N terminus of each N28Fd molecule. The two cysteines in one N28Fd molecule are expected to form two disulphide bonds with one of the two cysteines at the N termini of other two N28Fd molecules, respectively, in the ccN28Fd trimer, resulting in the formation of a highly stable NHR-trimer because both ends of the trimer are fixed by disulphide bonds and Fd, respectively (Figure 1) .
The designed protein, ccN28Fd, was solubly expressed in prokaryotic E. coli with more than 5 mg of protein per litre of culture in laboratory flasks. As expected, ccN28Fd maintained trimeric conformation under both neutral (pH 7.2) and acidic (pH 3.0) conditions, while N28Fd became monomeric at pH 3.0, even though it formed a trimer at pH 7.2 ( Figure 2 ). N28FdE5R, which has an E5R mutation that disrupts the trimerization function of Fd, was in monomeric form at both pH 7.2 and pH 3.0. Sedimentation velocity analysis also confirmed that ccN28Fd was in trimeric form ( Figure 3) . Although ccN28Fd and N28Fd showed similar atypical a-helix by the presence of b-sheet domain of Fd, the six-helix bundle formed by ccN28Fd and C34 had much higher Tm value (798C) than that formed by N28Fd and C34 (648C), suggesting that the addition of two cysteines to the N terminus of the N28Fd The experiment was performed in triplicate and repeated once. The mean values from one representative experiment are presented. The ratio of the peptide ccN28Fd and tenofovir in combinations is 1 : 500 (in molecular concentration).
Tong et al. leads to increased thermostability and the enhanced binding affinity of ccN28Fd to the gp41 CHR region.
Besides strong acidic conditions in the vaginal tract (pH,4.5), another obstacle for developing vaginally usable protein/peptidebased microbicides is the existence of abundant proteolytic enzymes in the vagina, which may hydrolyse the protein/peptide drugs and shorten their half-lives. Strikingly, ccN28Fd is highly resistant to protease cleavage, compared with N28Fd. After a 4 h treatment with proteinase K, ccN28Fd remained intact with .90% of its anti-HIV-1 activity, while N28Fd was almost completely degraded with the loss of most of its antiviral activity (Figure 7) . Similarly, ccN28Fd was highly resistant to treatment by pepsin in HCl (pH 1.5) for 4 h, whereas N28Fd retained only 30% of the original amount and fully lost its anti-HIV-1 activity. These results indicate that ccN28Fd may have much longer half-life than N28Fd when it is vaginally applied as a topical microbicide.
Interestingly, stabilization of the NHR-trimeric coiled coil also resulted in significantly increased anti-HIV-1 potency of ccN28Fd. The inhibitory activity of ccN28Fd against infection by HIV-1 IIIB (X4 virus) and Bal (R5 virus) was 18.3-and 23-fold higher than that of N28Fd, respectively, and 6.4-and 10.2-fold higher than that of enfuvirtide ( Figure 5 ). One possible mechanism of the increased antiviral activity is that the three monomers of ccN28Fd associate with each other more tightly than those in N28Fd, which causes the decreased hydrodynamic radius and makes it much easier for the trimer of ccN28Fd to access to the CHR of HIV-1 gp41 than the trimer of N28Fd.
We also found that ccN28Fd was highly effective (IC 50 ¼30.5 nM) in blocking the transmission of HIV-1 Bal from PBMCs to CEMx174 5.25M7 cells (Figure 6 ). Unlike ionic polymer-based microbicide candidates that are much less effective against R5 viruses, these results suggest that ccN28Fd has similar efficacy against both R5 and X4 viruses. Moreover, ccN28Fd could inhibit infection by a broad spectrum of primary HIV-1 isolates with distinct genotypes (subtypes A, B, C, D, A/E, F and O) and phenotypes (X4, X4/R5 and R5) in a range of 3-75 nM (Table 1) . It is also effective in inhibiting infection by enfuvirtide-resistant strains (Table 2) . Thus, for the development of anti-HIV microbicides, these results indicate that ccN28Fd has more potential than either N28Fd or enfuvirtide since it is highly effective against a broad spectrum of HIV-1 strains, including those resistant to the currently used anti-HIV drugs, such as enfuvirtide.
One important lesson that we have learned from others' experience in developing surfactant-based microbicides is that toxicity of the surfactants to vaginal mucosal tissue is responsible for the failure of the trials on these microbicides. 54 Therefore, in this study, we tested potential cytotoxicity of ccN28F to the human vaginal epithelial cell lines (VK2/E6E7) and the target cells (MT-2 and TZM-bl) that we used for testing antiviral activity. As shown in Figure S2 , ccN28Fd exhibited no significant in vitro cytotoxicity to these cells at a concentration as high as 10 mM, suggesting that it may also have no toxic effect on the vaginal/cervical tissues when it is used vaginally as a topical microbicide.
Vaginal microbicides are commonly administered by formulating an aqueous mucoadhesive gel. 55 -57 The antiviral potency of an ideal microbicide should not be significantly decreased when it is released from the gel or in the presence of human vaginal secretion or semen. Our study showed that solution from ccN28Fd gel formulation remained at a high level of antiviral potency against HIV-1 infection and that the presence of vaginal fluid simulant and seminal fluid had no significant effect on the antiviral potency of ccN28Fd ( Figure S1 , available as Supplementary data at JAC Online), suggesting that ccN28F is suitable for further development as an effective and safe anti-HIV microbicide.
Because of long-term application of ART in HIV/AIDS patients, the emergence of multidrug-resistant HIV-1 variants has posed a challenge for the design of highly effective microbicides. Consequently, the combination of microbicides consisting of anti-HIV agents with different mechanisms of action is expected to have synergistic anti-HIV-1 activity against a broad spectrum of HIV-1 strains, including those resistant to the currently used anti-HIV drugs. 17 Veazey et al. 21 reported that the CCR5 receptor antagonist CMPD167 could fully protect macaques from infection by SHIV (162P4), but only in combination with BMS-378806, an HIV attachment targeting gp120, and C52-L, an HIV fusion inhibitory peptide targeting gp41. In the present study, we demonstrated that the combination of ccN28Fd with tenofovir, an NRTI, resulted in strong synergism against HIV-1 IIIB (X4 virus) and Bal (R5 virus) with combination index values in the range of 0.1 -0.3 (Table 3) and dose reductions ranging from 10-to 22-fold. These results suggest that ccN28Fd, as a stable HIV entry inhibitor targeting viral gp41, can be combined with an NRTI or NNRTI to develop a highly effective and safe microbicide combination for preventing sexual transmission of HIV.
